A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
Patients with obesity-related heart failure with preserved ejection fraction (HFpEF) display circulatory volume expansion and pressure overload contributing to cardiovascular-kidney end-organ damage. In the SUMMIT trial, patients with HFpEF and obesi…
AIMS: To explore how Tirzepatide (TZP) treatment influences diet-related quality of life (QoL) and thus treatment satisfaction. METHODS: This retrospective observational study analyzed 95 people with type 2 diabetes mellitus treated with TZP. We eval…
AIMS: Doxorubicin (DOX), an effective and commonly used chemotherapeutic agent, often triggers dosage-dependent and potentially lethal cardiotoxicity, which heavily limits its clinical application in cancer survivors. However, no actual pharmacologic…
The primary objective of this review is to analyze the effects on body weight of discontinuing therapy with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or tirzepatide in patients treated for obesity. In recent months, there has been a consi…
BACKGROUND: Obesity and associated metabolic disorders such as type 2 diabetes mellitus and polycystic ovary syndrome are rising globally, contributing to infertility and adverse pregnancy outcomes. This review synthesizes current evidence on pharmac…
Jastreboff AM, Aronne LJ, Ahmad NN,Tirzepatide Once Weekly for the Treatment of Obesity.2022;387:205-216.
AIMS: This meta-analysis evaluates the rates of pancreatitis/pancreatic cancer among glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in randomised controlled trials (RCTs). METHODS: Following the Preferred Reporting Items for Systematic Reviews…
Obesity in non-diabetic adults remains a significant clinical challenge, prompting the need for effective pharmacological therapies that achieve meaningful weight loss with acceptable tolerability. Semaglutide, a selective glucagon-like peptide-1 (GL…
The introduction of tirzepatide marks a significant advancement in the management of type 2 diabetes mellitus (T2DM) and obesity. This dual synthetic polypeptide, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-1 recepto…
BACKGROUND: Prescription of obesity medications is increasing, but our understanding of their effects in patients with cardiovascular disorders, such as postural orthostatic tachycardia syndrome (POTS), is limited. CASE SUMMARY: POTS was exacerbated…
PURPOSE: The purpose of this study was to understand real-world use of Tirzepatide among people without type 2 diabetes (T2D) diagnoses in the United States in the MerativeMarketScan® Commercial (MarketScan) and Optum Clinformatics Claims (CDM) datab…
OBJECTIVES: With the increasing use of GLP-1 receptor agonist (GLP-1 RA) drugs for weight loss and diabetes management, concerns have been raised regarding their potential side effects. We aim to assess the frequency of otolaryngologic adverse events…
INTRODUCTION: According to the Obesity Medicine Association, obesity is a chronic, progressive, relapsing, multifactorial and treatable neurobehavioral disease. A small number of drugs have been approved by the Food & Drug Administration (FDA) for we…
BACKGROUND: Incretin-based therapies are used to treat type 2 diabetes and obesity, but the presence of diabetes diminishes the magnitude of weight loss produced by these drugs in people with obesity. It is not known whether this attenuated weight ch…